Diabetes and second-generation (atypical) antipsychotics;Diabète et antipsychotiques de seconde génération

Annales d'Endocrinologie

Volumn 70, Issue 4, 2009, Pages 202-210

  Chabroux, S ^a   Haffen, E ^b   Penfornis, A ^a  

^a UNIVERSITY HOSPITAL JEAN MINJOZ   (France)

^b HÔPITAL SAINT JACQUES   (France)

Author keywords

Antipsychotics; Diabetes; Dyslipidemia; Obesity; Schizophrenia

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CHLORPROMAZINE; CLOZAPINE; CYAMEMAZINE; FLUPHENAZINE; HALOPERIDOL; INSULIN; LEVOMEPROMAZINE; LOXAPINE; LOXAPINE SUCCINATE; MESORIDAZINE; MESORIDAZINE BESYLATE; NEUROLEPTIC AGENT; OLANZAPINE; PERICIAZINE; PERPHENAZINE; PIMOZIDE; PIPAMPERONE; PIPOTIAZINE; PROCHLORPERAZINE; PROCHLORPERAZINE MALEATE; QUETIAPINE; RISPERIDONE; SERTINDOLE; SULPIRIDE; THIORIDAZINE; TRIFLUOPERAZINE; TRIFLUPROMAZINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZIPRASIDONE; ZOLEPTIL; ZOTEPINE;

DIABETES MELLITUS; DRUG EFFICACY; DRUG TOLERABILITY; DYSLIPIDEMIA; EXTRAPYRAMIDAL SYMPTOM; HUMAN; INSULIN RELEASE; INSULIN RESISTANCE; OBESITY; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR; SCHIZOPHRENIA; SHORT SURVEY;

ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANTIPSYCHOTIC AGENTS; DIABETES COMPLICATIONS; DIABETES MELLITUS; HUMANS; SCHIZOPHRENIA;

EID: 69949084943     PISSN: 00034266     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ando.2009.07.003     Document Type: Short Survey

References (63)

1. Llorca PM. La schizophrénie. Encyclopédie Orphanet, janvier 2004 ; http://www.orpha.net/data/patho/FR/fr-schizo.pdf.
2. Petitjean F, Marie-Cardine M. Schizophrénies debutantes : diagnostic et modalités thérapeutiques. Paris: John Libbey Eurotext et Fédération française de Psychiatrie ; 2003, ISBN 2742004483.
3. Craddock N., O'Donovan M.C., and Owen M.J. Genes for schizophrenia and bipolar disorders? Implications for psychiatric nosology. Schizophr Bull 32 (2006) 9-16
4. Cardno A.G., Marshall E.J., Coid B., Macdonald A.M., Ribchester T.R., Davies N.J., et al. Heritability estimates for psychotic disorders: the Maudsley twin psychosis series. Arch Gen Psychiatry 56 (1999) 162-168
5. Kendler K.S., McGuire M., Gruenberg A.M., O'Hare A., Spellman M., and Walsh D. The Roscommon Family Study. 1 Methods, diagnosis of probands, and risk of schizophrenia in relatives. Arch Gen Psychiatry 50 (1993) 527-540
6. Picchioni M.M., and Muray R.M. Schizophrenia. BMJ 335 (2007) 91-95
7. Stefansson H., Rujescu D., Cichon S., Pietilainen O.P., Ingason A., Steinberg S., et al. Large recurrent microdeletions associated with schizophrenia. Nature 455 (2008) 232-236
8. International Schizophrenia Consortium. Rare chromosomal deletions and duplications increase risk of schizophrenia. Nature 2008;455:237-41.
9. Meyer-Lindenberg A., Miletich R.S., Kohn P.D., Esposito G., Carson R.E., Quarantelli M., et al. Reduced prefrontal activity predicts exaggerated striatal dopaminergic function in schizophrenia. Nat Neurosci 5 (2002) 267-271
10. Haw C., and Stubbs J. Combined antipsychotics for "difficult to manage" and forensic patients with schizophrenia: reasons for prescribing and perceived benefits. Psychiatr Bull 27 (2003) 449-452
11. Keefe R.S., Bilder R.M., Davis S.M., Harvey P.D., Palmer B.W., Gold J.M., et al. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Arch Gen Psychiatry 64 (2007) 633-647
12. Jones P.B., Barnes T.R., Davies L., Dunn G., Lloyd H., Hayhurst K.P., et al. Randomized controlled trial of the effect on Quality of Life of second-vs first-generation antipsychotic drugs in schizophrenia: cost utility of the latest antipsychotic drugs in schizophrenia study (CUTLASS 1). Arch Gen Psychiatry 63 (2006) 1079-1087
13. Saari K.M., Lindeman S.M., Viilo K.M., Isohanni M.K., Jarvelin M.R., Lauren L.H., et al. A 4-fold risk of metabolic syndrome in patients with schizophrenia: The Northern Finland 1966 Birth Cohort study. J Clin Psychiatry 66 (2005) 559-563
14. Bishop J.R., Ellingrod V.L., Moline J., and Miller D. Pilot study of the G-protein beta3 subunit gene (C825T) polymorphism and clinical response to olanzapine or olanzapine-related weigh gain in persons with schizophrenia. Med Sci Monit 12 (2006) BR47-50
15. Souza R.P., De Luca V., Muscettola G., Rosa D.V., de Bartholomeis A., Romano Silva M., et al. Association of antipsychotic induced weight gain and body mass index with GNB3 gene: a meta-analysis. Prog Neuropsychopharmacol Biol Psychiatry 32 (2008) 1848-1853
16. American Diabetes Association Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004; 27:596-601.
17. Suvisaari J.M., Saarni S.I., Perala J., Suvisaari J.V., Harkanen T., Lonnqvist J., et al. Metabolic syndrome among persons with schizophrenia and other psychotic disorders in a general population survey. J Clin Psychiatry 68 (2007) 1045-1055
18. Kato M.M., Currier M.B., Villaverde O., and Gonzalez-Blanco M. The relationship between body fat distribution and cardiovascular risk factors in patients with schizophrenia: a cross-sectional pilot study. Prim Care Companion. J Clin Psychiatry 7 (2005) 115-118
19. De Hert M.A., van Winkel R., Van Eyck D., Hanssens L., Wampers M., Scheen A., et al. Prevalence of the metabolic syndrome in patients with schizophrenia treated with antipsychotic medication. Schizophr Res 83 (2006) 87-93
20. Casey D.E. Metabolic issues and cardiovascular disease in patients with psychiatric disorders. Am J Med 118 Suppl. 2 (2005) 15S-22S
21. Mukherjee S., Schnur D.B., and Reddy R. Family history of type 2 diabetes in schizophrenic patients. Lancet 1 (1989) 495
22. Bellivier F. Schizophrenia, antipsychotics and diabetes: genetic aspects. Eur Psychatry 20 Suppl. 4 (2005) S335-S339
23. Lindenmayer J.P., Czobor P., Volavka J., Citrome L., Sheitman B., McEvoy J.P., et al. Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. Am J Psychiatry 160 (2003) 290-296
24. Newcomer J.W., Haupt D.W., Fucetola R., Melson A.K., Schweiger J.A., Cooper B.P., et al. Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. Arch Gen Psychiatry 59 (2002) 337-345
25. Smith M., Hopkins D., Peveler R.C., Holt R.I., Woodward M., and Ismail K. First-v. second generation antipsychotics and risk for diabetes in schizophrenia: a systematic review and meta-analysis. Br J Psychiatry 192 (2008) 406-411
26. Lieberman J.A., Stroup T.S., McEvoy J.P., Swartz M.S., Rosenheck R.A., Perkins D.O., et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353 (2005) 1209-1223
27. Newcomer J.W. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 19 Suppl. 1 (2005) 1-93
28. De Hert M., Hanssens L., van Winkel R., Wampers M., van Eyck D., Scheen A., et al. A case series: evaluation of the metabolic safety of aripiprazole. Schizophr Bull 33 (2007) 823-830
29. Koller E.A., Cross J.T., Doraiswamy P.M., and Schneider B.S. Risperidone-associated diabetes mellitus: a pharmacovigilance study. Pharmacotherapy 23 (2003) 735-744
30. Koller E., Schneider B., Bennett K., and Dubitsky G. Clozapine-associated diabetes. Am J Med 111 (2001) 716-723
31. Koller E.A., and Doraiswamy P.M. Olanzapine-associated diabetes mellitus. Pharmacotherapy 22 (2002) 841-852
32. Koller E.A., Weber J., Doraiswamy P.M., and Schneider B.S. A survey of reports of quetiapine-associated hyperglycemia and diabetes mellitus. J Clin Psychiatry 65 (2004) 857-863
33. Regenold W.T., Thapar R.K., Marano C., Gavirneni S., and Kondapavurulu P.V. Increased prevalence of type 2 diabetes mellitus among psychiatric inpatients with bipolar, affective and schizoaffective disorders independent of psychotropic drug use. J Affect Disord 70 (2002) 19-26
34. Gardner D.M., Baldessarini R.J., and Waraich P. Modern antipsychotic drugs: a critical overview. CMAJ 172 (2005) 1703-1711
35. Citrome L.L., and Jaffe A.B. Relationship of atypical antipsychotics with development of diabetes mellitus. Ann Pharmacother 37 (2003) 1849-1857
36. Nemeroff C.B. Dosing the antipsychotic medication olanzapine. J Clin Psychiatry 58 Suppl 10 (1997) 45-49
37. Casey D.E., Haupt D.W., Newcomer J.W., Henderson D.C., Sernyak M.J., Davidson M., et al. Antipsychotic-induced weight gain and metabolic abnormalities: implications for increased mortality in patients with schizophrenia. J Clin Psychiatry 65 Suppl. 7 (2004) 4-18
38. Davidson M., Emsley R., Kramer M., Ford L., Pan G., Lim P., et al. Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): results of a 6-week, randomized, placebo-controlled study. Schizophr Res 93 (2007) 117-130
39. Kurzthaler I., and Fleischhacker W.W. The clinical implications of weight gain in schizophrenia. J Clin Psychiatry 62 Suppl. 7 (2001) 32-37
40. Allison D.B., Mentore J.L., Heo M., Chandler L.P., Cappelleri J.C., Infante M.C., et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 156 (1999) 1686-1696
41. Newcomer J.W., and Sernyak M.J. Identifying metabolic risks with antipsychotics and monitoring and management strategies. J Clin Psychiatry 68 (2007) e17
42. Ader M., Kim S.P., Catalano K.J., Ionut V., Hucking K., Richey J.M., et al. Metabolic dysregulation with atypical antipsychotics occurs in the absence of underlying disease: a placebo-controlled study of olanzapine and risperidone in dogs. Diabetes 54 (2005) 862-871
43. Johnson D.E., Yamazaki H., Ward K.M., Schmidt A.W., Lebel W.S., Treadway J.L., et al. Inhibitory effects of antipsychotics on carbachol-enhanced insulin secretion from perifused rat islets: role of muscarinic antagonism in antipsychotic-induced diabetes and hyperglycemia. Diabetes 54 (2005) 1552-1558
44. Scheen A.J., and De Hert M. Drug-induced diabetes mellitus: the example of atypical antipsychotics. Rev Med Liege 60 (2005) 455-460
45. Naranjo C.A., Busto U., Sellers E.M., Sandor P., Riuz I., Roberts E.A., et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 30 (1981) 239-245
46. Makhzoumi Z.H., McLean L.P., Lee J.H., and Ibe A.I. Diabetic ketoacidosis associated with aripiprazole. Pharmacotherapy. 28 (2008) 1198-1202
47. Reddymasu S., Bahta E., Levine S., Manas K., and Slay L.E. Elevated lipase and diabetic ketoacidosis associated with aripiprazole. JOP 7 (2006) 303-305
48. Borot S., Kleinclauss C., Chabroux S., and Penfornis A. Olanzapine et diabète : un cas d'auto-anticorps anti-GAD et IA2 induit ?. Diabetes Metab 32 (2006) S42
49. Scheen A.J. Current management strategies for coexisting diabetes mellitus and obesity. Drugs 63 (2003) 1165-1184
50. Umpierrez G.E., Smiley D., and Kitabchi A.E. Narrative review: ketosis-prone type 2 diabetes mellitus. Ann Intern Med. 144 (2006) 350-357
51. Expert group "Schizophrenia and Diabetes 2003". Expert Consensus Meeting, Dublin, 3-4 October 2003: consensus summary. Br J Psychiatry 2004; 47:S112-4.
52. Lambert T.J., Chapman L.H., and the Consensus Working Group. Diabetes, psychotic disorders and antipsychotic therapy: a consensus statement. Med J Aust 181 (2004) 544-548
53. De Nayer A., De Hert M., Scheen A., Van Gaal L., and Peuskens J. Conference report: Belgian consensus on metabolic problems associated with atypical antipsychotics. Encephale 33 (2007) 197-202
54. Barnett A.H., Mackin P., Chaudhry I., Farooqi A., Gadsby R., Heald A., et al. Minimising metabolic and cardiovascular risk in schizophrenia: diabetes, obesity and dyslipidaemia. J Psychopharmacol 21 (2007) 357-373
55. Marder S.R., Essock S.M., Miller A.L., Buchanan R.W., Casey D.E., Davis J.M., et al. Physical health monitoring of patients with schizophrenia. Am J Psychiatry 161 (2004) 1334-1349
56. Newcomer J.W. Metabolic syndrome and mental illness. Am J Manag Care 13 (2007) S170-S177
57. Jacob R., and Chowdhury A.N. Metabolic comorbidity in schizophrenia. Indian J Med Sci 62 (2008) 23-31
58. Kanders B.S., Forse R.A., and Blackburn G.L. Methods in obesity. In: Rakel R.E. (Ed). Conn's Current Therapy (1991), WB Saunders, Philadelphia, Pa 524-532
59. Pasternak R.C. Report of the Adult Treatment Panel III: the 2001 National Cholesterol Education Program guidelines on the detection, evaluation and treatment of elevated cholesterol in adults. Cardiol Clin 2 (2003) 393-398
60. Wu R.R., Zhao J.P., Jin H., Shao P., Fang M.S., Guo X.F., et al. Lifestyle intervention and metformin for treatment of antipsychotic-induced weight gain: a randomised controlled trial. JAMA 299 (2008) 185-193
61. Vandel P, Haffen E, Sechter D. Traitement chimiothérapique des schizophrénies. EMC (Elsevier Masson SAS, Paris), Psychiatrie, 37-295-A-10, 2008.
62. Alvarez-Jimenez M., Gonzalez-Blanch C., Crespo-Facorro B., Hetrick S., Rodriguez-Sanchez J.M., Perez-Iglesias R., et al. Antipsychotic-induced weigh gain in chronic and first-episode psychotic disorders: a systematic critical reappraisal. CNS Drugs 22 (2008) 547-562
63. Marder S.R., Essock S.M., Miller A.L., Buchanan R.W., Davis J.M., and Kane J.M. The Mount Sinaï conference on the pharmacotherapy of schizophrenia. Schizophr Bull 28 (2002) 5-16